Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination

Marco Zimarino; Giulia Renda; Nicola Maddestra; Raffaele De Caterina

doi:10.1055/s-0037-1613740

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 92(03): 668-669
DOI: 10.1055/s-0037-1613740

Case Report

Schattauer GmbH

Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination

Marco Zimarino

¹Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy

,

Giulia Renda

¹Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy

,

Nicola Maddestra

¹Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy

,

Raffaele De Caterina

¹Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy

› Author Affiliations

Abstract

Full Text

References

References
1 Bertrand ME, Rupprecht HJ, Urban P. et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-9.
2 Morice MC, Serruys PW, Sousa JE. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
3 Moses JW, Leon MB, Popma JJ. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
4 Stone GW, Ellis SG, Cox DA. et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
5 FDA Public Health Web Notification: Information for Physicians on Subacute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER Coronary Stent. Issued October 29, 2003. Available at: http://www.fda.gov/cdrh/safety/ cypher.html
6 Schofer J, Schluter M, Gershlick AH. et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-9.
7 Lemos PA, Serruys PW, van Domburg RT. et al. Unrestricted utilization of sirolimuseluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109: 190-5.
8 Chieffo A, Bonizzoni E, Orlic D. et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 2004; 109: 2732-6.
9 Jeremias A, Sylvia B, Bridges J. et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-2.
10 Kerner A, Gruberg L, Kapeliovich M. et al. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv 2003; 60: 505-8.
11 Virmani R, Guagliumi G, Farb A. et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 2004; 109: 701-5.
12 Mehta SR, Yusuf S, Peters RJ. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
13 Steinhubl SR, Berger PB, Mann 3rd JT. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Jama 2002; 288: 2411-20.